No Data
Clear Street Launches Healthcare & Biotechnology Equity Research
Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic
Century Therapeutics Faces Termination of BMS Agreement
Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's...
Express News | Century Therapeutics - to Evaluate Opportunities in Aml and Multiple Myeloma
Express News | Century Therapeutics - Termination Effective March 12, 2025